Take­da se­lects for­mer CRISPR Ther­a­peu­tics CMO to lead on­col­o­gy unit; Emile Nuwaysir out at En­so­ma

→ A spokesper­son for Take­da tells Peer Re­view that PK Mor­row suc­ceed­ed Chris Arendt as head of on­col­o­gy on Jan. 29. A few weeks ago we told you about Mor­row’s res­ig­na­tion as CMO of CRISPR Ther­a­peu­tics, and a re­place­ment has not been named at Ver­tex’s Cas­gevy part­ner. Mor­row held a num­ber of po­si­tions over a decade at Am­gen, in­clud­ing VP and glob­al ther­a­peu­tic area head of hema­tol­ogy, GI on­col­o­gy, GU on­col­o­gy and bone dis­eases. Arendt vault­ed to CSO and head of re­search last fall at the Japan­ese phar­ma, which will el­e­vate Mi­lano Fu­ru­ta to CFO in April.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER